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A B S T R A C T
There is a need to identify early disease markers to facilitate diagnosis of mucopolysaccharidosis type II (MPS II;
Hunter syndrome). Mean birth weight and its association with disease severity was investigated in 609 patients
enrolled in the Hunter Outcome Survey (HOS). This analysis indicated that birth weight is not an early marker of
MPS II and is not associated with disease severity. It remains important to investigate the utility of other factors
for early/pre-symptomatic diagnosis.
1. Introduction
Mucopolysaccharidosis type II (MPS II; Hunter syndrome; OMIM#
30990) is a rare, progressive, X-linked disorder caused by deﬁciency of
the lysosomal enzyme iduronate-2-sulfatase (EC 3.1.6.13) [1]. The
severity of MPS II spans a broad range; although all patients experience
somatic disease manifestations, about two-thirds of patients display
progressive central nervous system (CNS) involvement, which is absent
in the remaining patients [1,2]. The variable clinical presentation of
MPS II, non-speciﬁc signs and symptoms that are similar to common
childhood ailments, and a lack of disease awareness, means that
diagnosis is challenging and frequently delayed [3]. Speciﬁc treatment
is available in the form of weekly enzyme replacement therapy (ERT)
with intravenous idursulfase (Elaprase®, Shire, Lexington, MA, USA).
Since timely diagnosis and treatment initiation may improve patient
outcomes, the identiﬁcation of early disease markers is critical,
especially those that could indicate a need for screening at birth [3].
Previous studies have analysed birth parameters in patients with
MPS II, and mean birth weight has been reported to be slightly higher in
patients with cognitive impairment than in those without [2,4–8].
However, many of these studies were conducted in small, restricted
patient populations and data on the correlation of birth weight with
disease severity are limited. Data available in the Hunter Outcome
Survey (HOS) were used to investigate whether birth weight diﬀers in
newborns with MPS II when compared with population-based reference
values, and whether there is an association with disease severity.
2. Materials and methods
2.1. Patient population
HOS is a large, multicenter, longitudinal, observational registry of
patients with MPS II that collects data on the natural history of the
disease and the long-term safety and eﬀectiveness of ERT with
idursulfase. Before enrolment, Independent Review Board/Ethics
Committee approval was obtained for all participating centers, and
each patient, their parents or a legal representative provided written
informed consent. For those patients who were deceased prior to HOS
entry, consent was obtained from patients' families. All patient infor-
mation in the registry is managed in accordance with national data
protection standards. Patients followed prospectively (alive at HOS
entry) and retrospectively (died before enrolment) were included in this
analysis. Brothers with the same date and place of birth but who were
not formally recorded in the database as twins, were excluded (as twins
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tend to have a lower birth weight than singletons) [9]. Patients with a
positive family history of MPS II or those for whom information on
family history of MPS II was missing were excluded from the analysis of
age at diagnosis.
2.2. Data analysis
HOS is designed to collect data on individuals diagnosed with MPS
II that has been obtained during routine patient visits and assessments
[2]. Data from patients who died before enrolment (retrospective
patients) may also be entered in the database. Birth weight for
gestational age z-scores (the number of standard deviations from the
reference mean) were calculated based on population-based reference
values [10]. To gauge the validity of the chosen reference population, a
comparison of mean birth weight in the overall analysis population
(n = 609) with that in a subgroup of the analysis population who were
of Caucasian origin (n = 463) was performed. Low birth weight for
gestational age was deﬁned as< 3rd percentile and high birth weight
for gestational age as> 97th percentile, based on population-based
reference values [10].
Disease severity was established on the basis of the presence or
absence of cognitive impairment at any time from birth to the last visit
recorded in HOS, based on the answer to the question ‘Cognitive
impairment? Yes/No’. A Student's t-test was used to assess the
signiﬁcance of diﬀerences in birth weight between patients with and
without cognitive involvement.
3. Results
As of January 2015, data on birth weight and gestational age were
available for 609 patients with MPS II who were enrolled in HOS. Of
these individuals, 516 were alive at HOS entry (prospective patients)
and 93 were deceased before enrolment (retrospective patients). A total
of 463 patients were of Caucasian origin (Table 1 and Supplementary
Table 1). As mean (standard deviation [SD]) birth weight in the
Caucasian sub-population was similar to that in the overall analysis
population (3430.2 [627.0] g and 3420.0 [621.5] g, respectively),
reference values from Kramer et al. [10] were used for the calculation
of birth weight for gestational age z-scores.
The mean birth weight for gestational age in patients with MPS II
was similar to that in the reference population, as demonstrated by a
mean [SD] birth weight for gestational age z-score of −0.03 [1.28]
(Table 1). The distribution of patients by birth weight for gestational
age z-score is shown in Supplementary Fig. 1. Approximately 6% of
patients (38/609) were considered to have a low birth weight for
gestational age, while almost 5% (29/609) had a high birth weight for
gestational age (Table 1). There was no apparent association between
birth weight and the presence or absence of cognitive impairment
(Table 1).
4. Discussion
Using data from over 600 individuals with MPS II, we found that the
mean birth weight of these patients is similar to that of the general
population. Our results from a large and diverse population of patients
conﬁrm the ﬁndings of previous smaller-scale studies, which have not
reported statistically signiﬁcant diﬀerences between the birth weights
of patients with MPS II and the general population [4,5,8]. In addition,
we found that birth weight was not associated with disease severity as
measured by the presence or absence of cognitive impairment. This is
an important ﬁnding, as anecdotal evidence and ﬁndings from other
studies have suggested that patients with cognitive impairment may
have higher birth weights than those without [4,6]. This is also
consistent with the lack of correlation between CNS involvement and
height, weight and head circumferences reported in older patients
[11,12].
As with any study using registry data, this analysis has several
potential limitations. Patient enrolment, data entry, and data collection
are at the discretion of participating physicians and there may be
regional variation in the methods used for obtaining clinical measure-
ments. In addition, other causes of high birth weight, such as maternal
diabetes, are not recorded in the database and so cannot be excluded. It
is also important to note that the assessment of cognitive impairment
recorded in HOS is not necessarily based on the results of standardized
cognitive tests but may instead be based on a brief, subjective, clinical
impression. In addition, the variable clinical presentation and rate of
progression of MPS II means that although some patients may display
little or no neurological involvement, they may be considered to have
severe disease on the basis of their somatic disease signs and symptoms.
Finally, as HOS only collects data from patients with MPS II we
compared birth weights with those from a Canadian reference popula-
tion, and so country-speciﬁc variation in birth weight is not accounted
for.
The accumulation of urinary glycosaminoglycans is thought to
begin prenatally [13,14], and so it is important that individuals with
MPS II are diagnosed and receive care as early as possible [15–17].
However, the early identiﬁcation of patients with the disease is
challenging, particularly in the absence of a positive family history of
the disease. This analysis indicates that birth weight is not a suitable
marker to facilitate newborn screening for MPS II. Thus, there remains a
Table 1
Birth weight in patients in this analysis (N = 609) and the relationship between birth weight and subsequent development of cognitive impairment.
Parameter Overall (N = 609) Patients with cognitive impairment status available (N = 578) p valuea
Cognitive impairment (N = 341) No cognitive impairment (N = 237)
Birth weight (all patients), g
Mean (SD) 3420.0 (621.5) 3426.2 (609.9) 3430.8 (620.9) 0.928
Median (10th, 90th percentiles) 3447.0b (2750.0, 4091.0) 3430.0 (2750.0, 4091.0) 3492.0 (2750.0, 4091.0)
z-Scorec
Mean (SD) −0.03 (1.28) −0.02 (1.19) 0.00 (1.42) 0.818
Median (10th, 90th percentiles) −0.04 (−1.54, 1.36) −0.04 (−1.54, 1.44) 0.00 (−1.52, 1.44)
Birth weight for gestational age category, n (%)d
Low (< 3rd percentile) 38 (6.2) 21 (58.3) 15 (41.7) N/A
Appropriate (≥3rd ≤97th percentile) 542 (88.9) 306 (59.5) 208 (40.5)
High (> 97th percentile) 29 (4.8) 14 (50.0) 14 (50.0)
N/A, non-applicable; SD, standard deviation.
a Cognitive impairment ‘Yes’ and cognitive impairment ‘No’ groups were compared using a Student's t-test.
b This value corresponds to the 58th percentile for boys (World Health Organization child growth standards) [18].
c Birth weight for gestational age z-score calculated according to population-based reference values [10].
d Percentiles calculated according to population-based reference values [10].
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need to investigate whether other factors or auxological data, such as
head circumference and body length at birth, may be indicators that
could be used to aid earlier, pre-symptomatic diagnosis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ymgmr.2017.02.004.
Role of the funding source
This study was sponsored and funded by Shire (Lexington, MA).
Data analysis was conducted by Shire under the direction of the
authors. No honoraria, grants or other forms of payment were made
to the authors for the writing of the manuscript. Medical writing
support was provided by Dr. Laura Pearce of Oxford PharmaGenesis
(Oxford, UK) and was funded by Shire.
Conﬂicts of interest
Olaf Bodamer: Dr. Bodamer has received research grants and
honoraria from Genzyme (a Sanoﬁ company) and Shire, and honoraria
from PTC.
Maurizio Scarpa: Dr. Scarpa has received grants, travel support and
honoraria from BioMarin, Genzyme (a Sanoﬁ company) and Shire.
Christina Hung: Dr. Hung has no conﬂicts of interest.
Tom Pulles: Dr. Pulles is a full-time employee of Ultragenyx
Pharmaceutical, Inc., and was previously a full-time employee and
shareholder of Shire.
Roberto Giugliani: Professor Giugliani has received travel grants
from BioMarin, Genzyme (a Sanoﬁ company) and Shire, research grants
from Actelion Pharmaceuticals, BioMarin, Genzyme (a Sanoﬁ com-
pany), Shire and Synageva BioPharma, and honoraria for speaking
engagements from BioMarin, Genzyme (a Sanoﬁ company), Shire and
Synageva BioPharma.
Contributors' statements
Olaf Bodamer: Dr. Bodamer made a substantial contribution to the
conception and design of the analysis and interpretation of data, drafted
the initial manuscript and revised it critically for important intellectual
content, approved the ﬁnal manuscript as submitted and agrees to be
accountable for all aspects of the work.
Maurizio Scarpa: Dr. Scarpa made a substantial contribution to the
conception and design of the analysis and interpretation of data, was
involved with developing the draft of the article and revising it
critically for important intellectual content, approved the ﬁnal manu-
script as submitted and agrees to be accountable for all aspects of the
work.
Christina Hung: Dr. Hung made a substantial contribution to the
conception and design of the analysis and interpretation of data, was
involved with developing the draft of the article and revising it
critically for important intellectual content, approved the ﬁnal manu-
script as submitted and agrees to be accountable for all aspects of the
work.
Tom Pulles: Dr. Pulles made a substantial contribution to the
conception and design of the analysis and interpretation of data, was
involved with developing the draft of the article and revising it
critically for important intellectual content, approved the ﬁnal manu-
script as submitted and agrees to be accountable for all aspects of the
work.
Roberto Giugliani: Professor Giugliani made a substantial contribu-
tion to the conception and design of the analysis and interpretation of
data, was involved with developing the draft of the article and revising
it critically for important intellectual content, approved the ﬁnal
manuscript as submitted and agrees to be accountable for all aspects
of the work.
Acknowledgements
Biostatistical support was provided by Shire. Editorial assistance
was provided to the authors by Dr. Laura Pearce of Oxford
PharmaGenesis (Oxford, UK) and was funded by Shire.
References
[1] E.F. Neufeld, J. Muenzer, The mucopolysaccharidoses, in: C.R. Scriver,
A.L. Beaudet, W.S. Sly, D. Valle, B. Childs, K.W. Kinzler, et al. (Eds.), The Metabolic
and Molecular Bases of Inherited Disease, eighth ed., McGraw-Hill, New York,
2001, pp. 3421–3452.
[2] J.E. Wraith, M. Beck, R. Giugliani, J. Clarke, R. Martin, J. Muenzer, Initial report
from the Hunter Outcome Survey, Genet. Med. 10 (2008) 508–516.
[3] B.K. Burton, R. Giugliani, Diagnosing Hunter syndrome in pediatric practice:
practical considerations and common pitfalls, Eur. J. Pediatr. 171 (2012) 631–639.
[4] I.V. Schwartz, M.G. Ribeiro, J.G. Mota, M.B. Toralles, P. Correia, D. Horovitz, et al.,
A clinical study of 77 patients with mucopolysaccharidosis type II, Acta Paediatr.
Suppl. 96 (2007) 63–70.
[5] A. Rozdzynska, A. Tylki-Szymanska, A. Jurecka, J. Cieslik, Growth pattern and
growth prediction of body height in children with mucopolysaccharidosis type II,
Acta Paediatr. 100 (2011) 456–460.
[6] P. Patel, Y. Suzuki, M. Maeda, E. Yasuda, T. Shimada, K.E. Orii, et al., Growth charts
for patients with Hunter syndrome, Mol. Genet. Metab. Rep. 1 (2014) 5–18.
[7] A. Rozdzynska-Swiatkowska, A. Jurecka, J. Cieslik, A. Tylki-Szymanska, Growth
patterns in children with mucopolysaccharidosis I and II, World J. Pediatr. 11
(2014) 226–231.
[8] A. Rozdzynska-Swiatkowska, A. Jurecka, Z. Zuber, A. Tylki-Szymanska, Can
macrosomia or large for gestational age be predictive of mucopolysaccharidosis
type I, II and VI? Pediatr Neonatol. (2015) S1875–S9572.
[9] United Nations Children's Fund, World Health, Low Birthweight: Country, Regional
and Global Estimates, UNICEF, New York, 2004.
[10] M.S. Kramer, R.W. Platt, S.W. Wen, K.S. Joseph, A. Allen, M. Abrahamowicz, et al.,
A new and improved population-based Canadian reference for birth weight for
gestational age, Pediatrics 108 (2001) E35.
[11] J. Marucha, A. Jurecka, M. Syczewska, A. Rozdzynska-Swiatkowska, A. Tylki-
Szymanska, Restricted joint range of motion in patients with MPS II: correlation
with height, age and functional status, Acta Paediatr. 101 (2012) e183–e188.
[12] S.A. Jones, R. Parini, P. Harmatz, R. Giugliani, J. Fang, N.J. Mendelsohn, The eﬀect
of idursulfase on growth in patients with Hunter syndrome: data from the Hunter
Outcome Survey (HOS), Mol. Genet. Metab. 109 (2013) 41–48.
[13] U.N. Wiesmann, M.A. Spycher, C. Meier, I. Liebaers, N. Herschkowitz, Prenatal
mucopolysaccharidosis II (Hunter): a pathogenetic study, Pediatr. Res. 14 (1980)
749–756.
[14] G. Baldo, U. Matte, O. Artigalas, I.V. Schwartz, M.G. Burin, E. Ribeiro, et al.,
Placenta analysis of prenatally diagnosed patients reveals early GAG storage in
mucopolysaccharidoses II and VI, Mol. Genet. Metab. 103 (2011) 197–198.
[15] A. Tylki-Szymanska, A. Jurecka, Z. Zuber, A. Rozdzynska, J. Marucha,
B. Czartoryska, Enzyme replacement therapy for mucopolysaccharidosis II from 3
months of age: a 3-year follow-up, Acta Paediatr. 101 (2012) e42–e47.
[16] G. Tajima, N. Sakura, M. Kosuga, T. Okuyama, M. Kobayashi, Eﬀects of idursulfase
enzyme replacement therapy for mucopolysaccharidosis type II when started in
early infancy: comparison in two siblings, Mol. Genet. Metab. 108 (2013) 172–177.
[17] J. Muenzer, Early initiation of enzyme replacement therapy for the mucopolysac-
charidoses, Mol. Genet. Metab. 111 (2014) 63–72.
[18] WHO Multicentre Growth Reference Study Group, WHO Child Growth Standards:
Length/Height-for-age, Weight-for-age, Weight-for-Length, Weight-for-Height and
Body Mass Index-for-age: Methods and Development, WHO, Geneva, 2006.
O. Bodamer et al. Molecular Genetics and Metabolism Reports 11 (2017) 62–64
64
